Literature DB >> 16101793

Treatment of canine Old World visceral leishmaniasis: a systematic review.

Chiara Noli1, Silvia T Auxilia.   

Abstract

Canine visceral leishmaniasis is a systemic disease caused by Leishmania infantum. The aim of this systematic review was to identify and evaluate the evidence of efficacy of interventions for treatment or prevention of canine visceral leishmaniasis, and to propose recommendations for or against their use. Forty-seven articles describing clinical trials published between 1980 and 2004 fulfilled selection criteria. The evaluation of clinical trials provided good evidence for recommending the use of meglumine antimoniate at a minimum dosage of 100 mg kg(-1) daily for at least 3-4 weeks, combined with allopurinol in order to obtain a good clinical efficacy and a reduced relapse rate. The evaluation of the articles also provided fair evidence for recommending the use of pentamidine (4 mg kg(-1) twice weekly) and aminosidine (5 mg kg(-1) twice daily) for 3-4 weeks. There was insufficient evidence for recommending the use of allopurinol alone, amphotericin B, buparvaquone, ketoconazole, enrofloxacin, and the combinations of metronidazole with spiramicyn or metronidazole with enrofloxacin. Fair evidence against the use of aminosidine at high dosages (20-80 mg kg(-1) per day) was proposed due to its side effects. Evaluation of articles on repellent measures against sand fly vectors of leishmaniasis provided good evidence for recommending deltamethrin collars and fair evidence for recommending spot-on permethrin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101793     DOI: 10.1111/j.1365-3164.2005.00460.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  38 in total

1.  Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds.

Authors:  M A Dea-Ayuela; S Rama-Iñiguez; J M Alunda; F Bolás-Fernandez
Journal:  Vet Res Commun       Date:  2007-01-19       Impact factor: 2.459

2.  Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

Authors:  Raul R Ribeiro; Eliane P Moura; Vitor M Pimentel; Weverton M Sampaio; Sydnei M Silva; Dante A Schettini; Cintia F Alves; Ferdinan A Melo; Wagner L Tafuri; Cynthia Demicheli; Maria N Melo; Frédéric Frézard; Marilene S M Michalick
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

3.  Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs.

Authors:  Felicitat Todolí; Inmaculada Galindo; Silvia Gómez-Sebastián; Mariano Pérez-Filgueira; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

4.  Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.

Authors:  Guadalupe Miró; Rosa Gálvez; Cristeta Fraile; Miguel A Descalzo; Ricardo Molina
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

5.  Canine leishmaniasis: the key points for qPCR result interpretation.

Authors:  Verónica Martínez; Javier Quilez; Armand Sanchez; Xavier Roura; Olga Francino; Laura Altet
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

6.  Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.

Authors:  Anna Maria Farca; B Miniscalco; P Badino; R Odore; P Monticelli; A Trisciuoglio; E Ferroglio
Journal:  Parasitol Res       Date:  2012-01-05       Impact factor: 2.289

7.  Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial.

Authors:  Angela Toepp; Mandy Larson; Tara Grinnage-Pulley; Carolyne Bennett; Michael Anderson; Molly Parrish; Hailie Fowler; Geneva Wilson; Katherine Gibson-Corely; Radhika Gharpure; Caitlin Cotter; Christine Petersen
Journal:  Am J Trop Med Hyg       Date:  2018-03-01       Impact factor: 2.345

8.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

9.  Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.

Authors:  Cristiano C P Dos Santos; Guilherme S Ramos; Renata C De Paula; Karen F Faria; Paulo O L Moreira; Ramon A Pereira; Maria N Melo; Wagner L Tafuri; Cynthia Demicheli; Raul R Ribeiro; Erly G Azevedo; Rubens Do Monte-Neto; Sydnei M Da Silva; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

10.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.